Mikel Sadek, MD
Surgery · New York, NYNPI 1063672764
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $82,490 of the $113,131 with a category attached, or 72.9%. Boston Scientific accounts for 81.7% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $34,724, 3.2 times the $10,905 reported in 2019. Among surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $595.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$92K
- Bard Peripheral Vascular, Inc.$12K
- Argon Medical Devices, Inc.$4K
- Cook Incorporated$1K
- Inari Medical, Inc.$943
- W. L. Gore & Associates, Inc.$567
- plus $2K from 15 others
Across 13 payments — averaging $3755.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$39K
- Boston Scientific$7K
- Veniti, Inc.$2K
What the payments were for
- Consulting fees$82,49073%
- Speaking & faculty fees$16,84615%
- Grants$420%
- Travel & lodging$7,3176%
- Food & beverage$6,3756%
- Entertainment$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 120 | $92,401 |
| Bard Peripheral Vascular, Inc. | 9 | $11,779 |
| Argon Medical Devices, Inc. | 5 | $4,367 |
| Cook Incorporated | 1 | $1,240 |
| Inari Medical, Inc. | 9 | $943 |
| W. L. Gore & Associates, Inc. | 3 | $567 |
| Baxter Healthcare | 8 | $528 |
| Cook Medical LLC | 5 | $234 |
| Humacyte Global, Inc. | 2 | $218 |
| Cardiovascular Systems Inc. | 2 | $154 |
| Johnson & Johnson | 9 | $152 |
| Endologix LLC | 1 | $113 |
| Abbott | 3 | $69 |
| Medtronic | 2 | $63 |
| Silk Road Medical, Inc. | 1 | $62 |
| Pfizer | 3 | $55 |
| Penumbra, Inc. | 2 | $53 |
| Terumo Medical Corporation | 1 | $42 |
| Angiodynamics, Inc. | 1 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| BD | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$31,519
- GENERAL VASCULAR INTERVENTION$17,843
- ANGIOJET$6,107
- Clot Management$3,917
- JETSTREAM SC$2,803
- ELUVIA$1,351
- Zilver Vena$1,240
- CT THROMBECTOMY SYSTEM KIT$692
- FLOWTRIEVER CATHETER, S$692
- RotarexS 6 F x 135 cm$615
- Product in Development$450
- AngioJet Ultra 5000A$450
- CLOT MGMT$450
- Varithena Administration Pack$334
- FlowTriever$195
- ClotTriever$195
- FLOSEAL$150
- Ovation$113
- Zenith Alpha$109
How this compares
$113,131 in reported general payments places this provider in the 95th percentile of 1,596 surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $81,109 |
| XareltoRivaroxaban | 63 | $51,972 |
| ClopidogrelClopidogrel Bisulfate | 176 | $1,778 |
| Cilostazol | 96 | $1,207 |
| Pentoxifylline | 14 | $223 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $55 | $81,109105 claims |
| Johnson & JohnsonXarelto | $152 | $51,97263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 surgery providers in New York.
Other surgery in New York
- Cheguevara AfanehNew York$1.4M
- Flavio Malcher Martins de OliveiraNew York$695K
- Yuri NovitskyNew York$548K
- Rasa ZarnegarNew York$478K
- Tanuja DamaniNew York$459K
- Rache SimmonsNew York$371K
- Marina KurianNew York$328K
- Megan JenkinsNew York$290K
- Brian JacobNew York$225K
- Robin BlackstoneNew York$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.